Clinical trial NCT03039621: Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children
Official title: International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Respiratory Viral Infections
Lead sponsor: Materia Medica Holding
Sponsor class: INDUSTRY
First posted: 2017-02-01
Enrollment: 287
Sex: ALL
Minimum age (years): 6
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The international multicenter double-blind placebo-controlled randomized clinical study in parallel groups.The objective of this study is to obtain additional data on the efficacy and safety of Ergoferon in the treatment of acute respiratory viral infections (ARVI) in children aged from 6 months to 6 years old.

Detailed description: Study design: international, multicenter double-blind placebo-controlled randomized clinical study in parallel groups.

The study will enroll patients of either gender aged from 6 months to 6 years old with clinical manifestations of ARVI within the first days after the onset of the disease. Patients will be included evenly (1:1 ratio) in accordance with the age group: 6 months - 3 years 11 months 29 days; 4 years - 6 years 11 months 29 days. Signed information sheet for parents/adopters (inform consent form) will be obtained from all participant's parents/ adopters prior to the screening procedures. Medical history, thermometry, patient examination by the doctor, assesment of ARVI symptoms severity and nasopharyngeal swabswill be performed at screening visit (Day 1).

If the inclusion criteria are met and exclusion criteria are absent, the patient is included in the study.

Nasopharyngeal swabs will be analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR) to identify the most common respiratory viruses, including (1) Influenza A virus; (2) Influenza B virus; (3) Influenza A (H1N1)pdm; (4) Human metapneumovirus; (5) Human respiratory syncytial virus; (6) Human rhinovirus; (7) Human adenovirus; (8) Human bocavirus; (9) Human parainfluenza virus 1; (10) Human parainfluenza virus 2; (11) Human parainfluenza virus 3; (12) Human parainfluenza virus 4; (13) Human coronavirus OC43; (14) Human coronavirus 229E; (15) Human coronavirus HKU1; (16) Human coronavirus NL63.

The patients are randomized into one of two groups: the 1st group patients will take Ergoferon according to the dosage regimen for 5 days; the 2nd group patients will take Placebo according to the dosage regimen of Ergoferon for 5 days. Patient's parents/ adoptive parents are provided with diares, where daily in the morning and at hight they record oral temperature (measured by a digital thermometer provided by Sponsor), symptoms of ARVI (according to the 4-points scale), administered drug and concomitant therapy. The doctors instruct parents/ adoptive parents how to fill in the diaries; the first scores of ARVI symptoms severity and oral temperature are made by doctors together with the parents/adoptive parents.

Patients are observed up for 14 days (screening and randomization - up to 1 day, therapy for 5 days, follow-up from 6 to 10 days; delayed telephone "visit" - on day 14).

During the observation period, two visits are planned (at home or at the medical center) on day 3 (Visit 2) and day 6 (Visit 3). If patients still have any symptoms of ARVI/ complications of ARVI, then an additional (unscheduled) Visit 4 is provided on Day 10 of the observation (at the medical center). During Visits 2, 3 (4), doctors carry out an physical examination, record dynamics of ARVI symptoms and concomitant therapy, check patient's diaries, which parents/adoptive parents return back at Visit 3 or 4. At Visit 3 (after 5 days of therapy) compliance with the treatment is additionally assessed. A "telephone visit" (Visit 5, Day 14 ± 1) is carried out to interview parents about the patient's condition, presence/ absence of complications, and possible use of antibiotics.

During the study, symptomatic therapy and therapy for underlying chronic conditions are allowed with the exception of the drugs indicated in the section "Prohibited Concomitant Therapy".

Eligibility criteria: Inclusion Criteria:

1. Patients of both genders aged from 6 months to 6 years old.
2. ARVI based on medical examination: oral temperature of at least 38.0°C at examination + total symptom severity ≥5.
3. The first 24 hours after ARVI onset.
4. Seasonal raise in ARVI incidence.
5. Availability of signed information sheet for parents/adopters(Informed Consent Form) for participation in the clinical trial.

Exclusion Criteria:

1. Suspected pneumonia or bacterial infection (e.g. meningitis, sepsis, otitis media, urinary tract infection, etc.) requiring a prescription of antibacterial product from the first day of the disease.
2. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic diseases of connective tissue, oncohaematological and other diseases).
3. Clinical symptoms of severe influenza infection/ARVI requiring hospitalization.
4. Medical history of primary and secondary immunodeficiency; oncologic conditions.
5. Aggravation or decompensation of chronic disease (diabetes mellitus, cerebral palsy, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of the respiratory and ETN organs/ear, throat, mouth, tongue, larynx, trachea, neck and salivary and thyroid glands, etc.) which affect the patient's ability to participate in the clinical study.
6. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
7. Allergy/hypersensitivity to any components of the drug product used in the therapy.
8. Course administration of the drug products specified in the section "Prohibited Concomitant Therapy" within two weeks prior to inclusion in the study.
9. Patients whose parents/adoptive parents will not fulfil the requirements during the study or follow the order of administration of the studied drug products from the investigator's point of view.
10. Participation in other clinical trials within 3 months prior to the enrollment in this study.
11. The patient's parent/adoptive parent is a study specialist at the centre and is directly involved in the study or is an immediate family member of the investigator. Spouses parents, children or siblings, regardless of whether they are siblings or adopted are considered immediate family members.
12. The patient's parent/adoptive parent works at OOO "NPF "MATERIA MEDICA HOLDING", i.e. they are employees of the Company, temporary employees on a contract basis or appointed official responsible for conduction of the study or their immediate family members.

Primary outcomes:
measure: Time to Alleviation of All ARVI Symptoms.
timeFrame: 14 days of observation.
Secondary outcomes:
measure: Time to Normalization of Body Temperature.
timeFrame: 14 days of observation.
measure: Time to Alleviation of Flu-like Nonspecific Symptoms.
timeFrame: 14 days of observation.
measure: Time to Alleviation of Respiratory Symptoms.
timeFrame: 14 days of observation.
measure: Flu-like Nonspecific and Respiratory Symptoms Total Score (TS) for Days 2-6.
timeFrame: On days 2-6 of the observation period.
measure: ARVI Severity.
timeFrame: On days 2-6 of the observation period.
measure: Percentage of Recovered Patients.
timeFrame: On days 2-6 of the observation period.
measure: Rates of Antipyretics Use Per Patient.
timeFrame: On days 1- 5 of the treatment period.
measure: Percentage of Patients With Worsening of Illness.
timeFrame: 14 days of observation peiod.
Other outcomes:
Locations:
city: Almaty
country: Kazakhstan
facility: Kazakh Medical Continuing Education University
city: Astana
country: Kazakhstan
facility: Astana Medical University
city: Karaganda
country: Kazakhstan
facility: Karaganda State Medical University
city: Ekaterinburg
country: Russian Federation
facility: Municipal autonomous institution "Children's City Clinical Hospital №11"
city: Kazan'
country: Russian Federation
facility: Federal State Budgetary Educational Institution of Higher Education "Kazan Medical University" of the Ministry of Healthcare of the Russian Federation
city: Moscow
country: Russian Federation
facility: Federal State Budgetary Educational Institution of Higher Education "Pirogov Russian National Research Medical University" of the Ministry of Healthcare of the Russian Federation
city: Moscow
country: Russian Federation
facility: Limited Liability Company "Diagnostics and Vaccines"
city: Moscow
country: Russian Federation
facility: St. Petersburg State Budgetary Health Care Institution "Сity Polyclinic №44"
city: Perm'
country: Russian Federation
facility: Municipal Health Care Institution "City Child Health Clinical Polyclinic №5"
city: Samara
country: Russian Federation
facility: State Budgetary Institution of Healthcare of the Samara Region "Samara City Children's Clinical Hospital named after N.N. Willow New
city: Volgograd
country: Russian Federation
facility: Volgograd State Medical University
city: Yaroslavl'
country: Russian Federation
facility: Yaroslavl State Medical University/Children's Clinic # 5
city: Yaroslavl'
country: Russian Federation
facility: Yaroslavl State Medical University/Clinical Hospital # 8
Study officials:
References: